Amgen Inc. Stock Falls Tuesday, Underperforms Market

Alkermes Plc

Change company Symbol lookup

Select an option...

ALKS Alkermes Plc

CPTNW Cepton Equity Warrant Exp 10th Feb 2027 *W EXP 02/10/2027

APPF Appfolio Inc

FMN Federated Hermes Premier Municipal Inc

USCTU TKB Critical Technologies 1

SIEGY Siemens AG

FDBC Fidelity D&D Bancorp Inc

$BUKCHET Bloomberg Coffee Subindex Euro

BMY Bristol-Myers Squibb Co

MLGO MicroAlgo Inc

Health Care : Biotechnology | Small Cap Growth
Based in Ireland

Company profile

Alkermes Public Limited Company is an integrated biopharmaceutical company. It is engaged in researching, developing and commercializing pharmaceutical products that are designed to address unmet medical needs of patients in the fields of neuroscience and oncology. Its portfolio of commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Its products include ARISTADA, ARISTADA INITIO, LYBALVI and VIVITROL. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder. VIVITROL is a non-narcotic, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.

Amgen Inc. Stock Falls Tuesday, Underperforms Market

4:38 pm ET November 29, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Amgen Inc. (AMGN) dropped 0.22% to $281.99 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.01% to 33,852.53 and the S&P 500 Index falling 0.16% to 3,957.63. This was the stock's second consecutive day of losses. Amgen Inc. closed $14.68 short of its 52-week high ($296.67), which the company achieved on November 8th.

The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Johnson & Johnson (JNJ) fell 0.70% to $176.09 and Pfizer Inc. (PFE) fell 0.16% to $49.49. Trading volume (2.1 M) remained 570,319 below its 50-day average volume of 2.7 M.

Data source: Dow Jones Market Data, FactSet. Data compiled November 29, 2022.

(END) Dow Jones Newswires

November 29, 2022 16:38 ET (21:38 GMT)